biostudies-literatureRoller AF. Hoffmann-La Roche Ltde008185https://www.ebi.ac.uk/biostudies/studies/S-EPMC11043740biostudies-literatureUnknown12(4)<h4>Background</h4>The immune status of a patient's tumor microenvironment (TME) may guide therapeutic interventions with cancer immunotherapy and help identify potential resistance mechanisms. Currently, patients' immune status is mostly classified based on CD8+tumor-infiltrating lymphocytes. An unmet need exists for comparable and reliable precision immunophenotyping tools that would facilitate clinical treatment-relevant decision-making and the understanding of how to overcome resistance mechanisms.<h4>Methods</h4>We systematically analyzed the CD8 immunophenotype of 2023 patients from 14 phase I-III clinical trials using immunohistochemistry (IHC) and additionally profiled gene expression by RNA-sequencing (RNA-seq). CD8 immunophenotypes were classified by pathologists into CD8-desert,Journal for immunotherapy of cancerTumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials.PMC11043740N/ACannarile MASerrano-Serrano MLValdeolivas AKorski KDavydov IIStaedler NDietmann GFerreira CSRoller AHeller ASchwalie PCKlaman IfalseTumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials.<h4>Background</h4>The immune status of a patient's tumor microenvironment (TME) may guide therapeutic interventions with cancer immunotherapy and help identify potential resistance mechanisms. Currently, patients' immune status is mostly classified based on CD8+tumor-infiltrating lymphocytes. An unmet need exists for comparable and reliable precision immunophenotyping tools that would facilitate clinical treatment-relevant decision-making and the understanding of how to overcome resistance mechanisms.<h4>Methods</h4>We systematically analyzed the CD8 immunophenotype of 2023 patients from 14 phase I-III clinical trials using immunohistochemistry (IHC) and additionally profiled gene expression by RNA-sequencing (RNA-seq). CD8 immunophenotypes were classified by pathologists into CD8-desert,2024-01-01T00:00:00Z2024 Apr2026-07-15T14:12:10.787Z2026-07-06T03:08:42.188ZS-EPMC110437403864928010.1136/jitc-2023-008185